Four-Drug attack on blood cancer shows promise in new trial

This study is testing a combination of four medications (daratumumab, carfilzomib, lenalidomide, and dexamethasone) as the first treatment for people newly diagnosed with multiple myeloma, a cancer of plasma cells in the bone marrow. It aims to see how well this combination works to eliminate or deeply control the cancer, measured by a very strict complete response and by checking for tiny amounts of leftover cancer cells. The trial will enroll about 75 adults who have not yet received chemotherapy for their myeloma.